Clinical trials: HIV 1 Infection
HIV Infections
The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients
To determine whether administration of a highly active antiretroviral treatment regimen consisting of ritonavir (ABT-538), zidovudine (AZT), and lamivudine (3TC) is associated with the restoration of delayed type hypersensitivity…
- Trial name
- NCT00001075
- Testing
- Ritonavir, Lamivudine, Zidovudine
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Severe Illness, Septicaemia
Early Versus Late BCG Vaccination in HIV-1 Exposed Infants in Uganda in Uganda
BCG vaccination may have non-specific effects (NSE) i.e., additional benefits on childhood morbidity and mortality that are separate the vaccine's effect on the incidence of disseminated tuberculosis.
- Conditions
- Severe Illness, Septicaemia, Diarrhoea, Lower Respiratory Infection
- Trial name
- NCT02606526
- Testing
- BCG at birth, Control arm: Delayed BCG
- Where
- Uganda
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Makerere University
HIV-1
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes).
- Trial name
- MERIT (NCT00098293)
- Testing
- Maraviroc + Zidovudine/Lamivudine, Efavirenz + Zidovudine/Lamivudine, Maraviroc (UK-427,857) + Zidovudine/Lamivudine
- Where
- 144 sites in United States, Argentina and 12 more
- Volunteers
- 916 people
- Sponsor
- ViiV Healthcare
HIV Infections
Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children
The purpose of this study is to see if it is safe and effective to give an anti-HIV drug combination of indinavir (IDV) plus stavudine (d4T) plus lamivudine (3TC) to HIV-infected children.
- Trial name
- NCT00000901
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 19 sites in United States, Puerto Rico
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
The purpose of this study is to determine the effect of treatment with Trizivir (TZV) plus efavirenz (EFV) or TZV alone on viral load (level of HIV in the blood).
- Trial name
- NCT00011895
- Testing
- Abacavir sulfate, Lamivudine and Zidovudine, Efavirenz
- Where
- 42 sites in United States
- Volunteers
- 400 people
- Sponsor
- GlaxoSmithKline
HIV-1, HIV Infections
Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers
Objectives: Primary: Safety and immunogenicity of MVA.HIVA vaccine in 20-week-old healthy Kenyan infants born to HIV-1-infected mothers.
- Trial name
- PedVacc002 (NCT00981695)
- Testing
- MVA.HIVA
- Where
- Kenya
- Volunteers
- 72 people
- Sponsor
- Medical Research Council
HIV-1-infection
Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance
This clinical trial will address the gap in published data on the effect of dolutegravir (DTG)-associated drug-resistant mutations on viral suppression among people remaining on DTG-based antiretroviral therapy.
- Trial name
- NCT06747507
- Testing
- Dolutegravir Pill, Darunavir+Ritonavir
- Where
- 9 sites in Kenya, Lesotho and 2 more
- Volunteers
- 392 people
- Sponsor
- University of Nairobi
HIV-1-infection
Improving HIV Prevention Among Adolescent Girls and Young Women (AGYW) in Uganda
Purpose: The purpose of the project is to evaluate a peer support intervention aimed at improving uptake of and adherence to oral PrEP.
- Trial name
- Peers for PREP (NCT05516602)
- Testing
- Peer Support
- Where
- Uganda
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
HIV/AIDS
PrEP My Way: A Hybrid Type 1 Clinical Effectiveness-implementation Trial to Promote PrEP Persistence Among Young Kenyan Women
PrEP My Way is a novel PrEP delivery system consisting of clinic-based PrEP initiation, followed by peer-delivered kits for HIV self-testing, PrEP refills, vaginal swabs for gonorrhea and chlamydia self-sampling, pregnancy tests…
- Trial name
- NCT06566430
- Testing
- PrEP My Way intervention, PrEP My Way intervention without STI testing, Enhanced standard of care
- Where
- Kenya
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Cognitive Disorders, HIV Infections
HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs
The purpose of this study is to see whether anti-HIV drugs that reduce HIV in the blood also reduce HIV in the cerebrospinal fluid (CSF). CSF is the fluid found around the brain and spinal cord.
- Trial name
- NCT00001103
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection
This study will determine the safety and tolerability of Fuzeon (enfuvirtide) used together with other treatments for HIV infection in patients with advanced HIV disease. Fuzeon is an antiretroviral drug.
- Trial name
- NCT00050856
- Testing
- Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give saquinavir (as a soft gel capsule taken by mouth) along with 2 other anti-HIV drugs to HIV-infected patients.
- Trial name
- NCT00002229
- Testing
- Saquinavir
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Study of Anti-HIV Therapy Intensification
The purpose of this study is to see how the body's immune system changes after replacing and adding new anti-HIV drugs to a patient's current anti-HIV therapy. This study will also see whether adding drugs is safe.
- Trial name
- NCT00034086
- Testing
- Lopinavir/Ritonavir, Lamivudine/Zidovudine, Tenofovir disoproxil fumarate
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection
This study was designed to provide early access to and evaluate the safety of TPV/r in PI-experienced patients with HIV-1 infection.
- Trial name
- NCT00097799
- Testing
- Tipranavir, Ritonavir
- Where
- 115 sites in United States
- Sponsor
- Boehringer Ingelheim
HIV-I Infection
Evaluation of Pre-Exposure Prophylaxis (PrEP) in Pregnant and Breastfeeding Women
The investigators will conduct an observational cohort study in 1200 pregnant women who will be recruited at the first antenatal care (ANC) visit from the Gugulethu and one additional facility in the Klipfontein-Mitchell's Plain…
- Trial name
- PrEP-PP (NCT03902418)
- Testing
- emtricitabine/tenofovir
- Where
- South Africa
- Volunteers
- 1,195 people
- Sponsor
- University of California, Los Angeles
HIV-1-infection, Multi-Antiviral Resistance
Italian Registry of HIV-1 Infected Patients With Drug-RESistant Virus to Reverse Transcriptase Inhibitors, InteGrasE and Viral Protease.
The PRESTIGIO Registry is an Observational, prospective, multicentre study that includes patients, regularly followed by Italian Infectious Disease Centres, with HIV-1 infection and documented resistance to the 4 classes of…
- Trial name
- PRESTIGIO (NCT04098315)
- Testing
- REGISTER CREATION
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Castagna Antonella
HIV-1
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
The purpose of this study is to evaluate the pharmacokinetics, safety and antiviral activity of rilpivirine (TMC278) 25 milligram (mg) or adjusted dose once daily in combination with an investigator-selected background regimen…
- Trial name
- NCT00799864
- Testing
- Rilpivirine, Zidovudine, Abacavir
- Where
- 17 sites in United States, India and 6 more
- Volunteers
- 54 people
- Sponsor
- Janssen Sciences Ireland UC
HIV Infections
A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients
The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.
- Trial name
- NCT00002236
- Testing
- Indinavir sulfate, Delavirdine mesylate, Zidovudine
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pharmacia and Upjohn
HIV Infections
Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents
First-line antiretroviral regimens are highly efficacious and generally well tolerated. However, as these regimens need to be taken life-long, there is growing concern about long-term toxicities associated with these regimens.
- Trial name
- NCT03682848
- Testing
- DTG + 3TC FDC
- Where
- 8 sites in Kenya, South Africa and 1 more
- Volunteers
- 32 people
- Sponsor
- ViiV Healthcare
HIV-1-infection
Uganda PrEP and Harm Reduction Evaluation
This is an evaluation of programs to integrate PrEP into existing services for PWUD. PrEP will be delivered according to Uganda national guidelines and data from national monitoring and evaluation forms will be leveraged to…
- Trial name
- NCT05040308
- Testing
- Integrating PrEP delivery
- Where
- Uganda
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Washington